MetaCap

Acrivon Therapeutics (ACRV) vs Aldeyra Therapeutics (ALDX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Acrivon Therapeutics (ACRV) has outperformed Aldeyra Therapeutics (ALDX) over the past year, losing 50.0% versus a loss of 83.1%. Aldeyra Therapeutics is the larger company by market cap ($50.7 million vs $49.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ACRV-50.00%ALDX-83.06%
+37%-29%-95%
Nov 21, 20251 yearNov 20, 2026
ACRV-92.71%ALDX-83.82%
+124%+10%-104%
Nov 14, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ACRV versus ALDX key metrics
MetricACRVALDX
Share price$1.15$0.84
Market cap$49.35M$50.70M
1-day change-17.86%+16.39%
YTD return-52.28%-83.78%
1-year return-50.00%-83.06%
5-year return—-89.06%
EPS (TTM)$-1.82$-0.31
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-77.91M$-33.85M
52-week high$3.56$5.93
52-week low$0.9709$0.527
Distance from 52-week high-67.70%-85.83%
Analyst consensusnonestrong_buy
Avg. price target upside+900.00%+685.71%
Average volume275.69K1.16M
Shares outstanding42.91M60.36M
Employees746
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ACRV has outperformed ALDX by 33.1 percentage points over the past year.

About Acrivon Therapeutics

ACRV stock →

Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.

Health Care · Biotechnology: Pharmaceutical Preparations · 74 employees

About Aldeyra Therapeutics

ALDX stock →

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.

Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees

ACRV vs ALDX FAQ

Which is bigger, Acrivon Therapeutics or Aldeyra Therapeutics?

Aldeyra Therapeutics (ALDX) is larger, with a market capitalization of $50.70M compared with $49.35M for Acrivon Therapeutics (ACRV).

Which stock has performed better over the past year, ACRV or ALDX?

ACRV returned -50.00% over the past 12 months, compared with -83.06% for ALDX (price return, excluding dividends). Past performance does not predict future results.

Are Acrivon Therapeutics and Aldeyra Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons